• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / RESEARCH . . . . / Cervarix Vaccine / HPV vaccination not cost effective

HPV vaccination not cost effective

July 15, 2013 By Norma Leave a Comment

HPV vaccination programs have been shown to be not cost effective in countries with comprehensive Pap screening and surgery

Abstract

By Judy Wilyman

Pap screening combined with loop electrosurgical excision procedures (LEEP) is almost 100% effective in preventing cervical cancer mortality yet many countries with these procedures have now implemented broad HPV vaccination programs. HPV vaccines have not been demonstrated to be more effective or safer than Pap screening in the prevention of cervical cancer and Pap screening will still be required even in vaccinated women. The HPV vaccine costs Au$450 per person and it does not protect against ~30% of cancer. This investigation analyses the cost-effectiveness of using the HPV vaccine in countries where Pap screening and surgical procedures have already reduced cervical cancer mortality to very low rates. Cost-effectiveness of vaccination programs is being determined by mathematical models which are founded on many assumptions. It is necessary to examine the rigor of these assumptions to be certain of the health benefits that are predicted. In 2002 scientists concluded that HPV 16 and 18 were the central and independent cause of most cervical cancer. This conclusion was based on molecular technology. If HPV 16 and 18 infections are the central and independent cause of most cervical cancer then the incidence of HPV 16 and 18 should vary with the incidence and mortality of cervical cancer worldwide. This correlation does not exist. It is also observed that the majority of HPV 16/18 infections do not lead to cervical cancer. This indicates that other etiological or ‘risk’ factors are necessary for persistent HPV infection to progress to cancer. The benefits of HPV vaccines have been determined by using pre-cancerous lesions in young women as a surrogate for cervical cancer. This surrogate is found to be inadequate as an end-point for cervical cancer. Clinical trials have only provided speculative benefits for the efficacy of HPV vaccines against cancer and the long-term risks of the vaccine have not been established. Pap screening will still be required in vaccinated women hence HPV vaccination programs are not cost-effective, and may do more harm than good, in countries where regular Pap screening and surgery has already reduced the burden of this disease. Also, they are not cost effective, or at least, have not been shown to be cost effective.

Background

Knowledge of the etiology of cervical cancer has been developed over the last century and during this time many lifestyle and environmental factors have been implicated in the etiology of this disease [1,2]. In 2002 it was stated that Human Papillomavirus (HPV) genotypes 16 and 18 are responsible for causing approximately 70% of cervical cancer worldwide [3]. This claim was made in 1995 based on the use of new hybridization technology for detecting HPV DNA that was stated to be ‘truly sensitive and specific’ [4]. Prior to 1995 the detection of HPV DNA in different tissues was known to be unreliable and the sensitivity of the results varied with the different techniques [5]. A causal theory based only on the presence of HPV genotypes is strongly dependent upon the accuracy and precision of the biotechnology used for detection [6]. Identification of HPV genotypes in the anogenital tract is also complicated by the fact that there are at least 40 HPV types present making it difficult to distinguish the causal factors for cervical cancer [6].

In 1995, Bosch et al. set out to characterise the global distribution of HPV genotypes because they knew this was ‘essential to the development of vaccination strategies to curb the burden of cervical cancer’ [7] p.797. In this study of 1000 cervical cancer tumors it was found that 93% contained HPV DNA [7]. This international study used new polymerase chain reaction-based (PCR) assays to detect more than 25 HPV types in 1000 specimens. In 1999, the 7% of tumors that were originally found to be HPV negative in the Bosch et al. study were re-analyzed using different techniques and assumptions [8]. After re-analysis Walboomers et al. claimed that 99.7% of tumors contained HPV DNA [8]. This evidence and other case–control studies led scientists to claim that persistent infection with HPV 16 and 18 is the main and determining factor in the etiology of most cervical cancer [3,8]. Consequently it was considered that a vaccine might be beneficial in reducing the global burden of cervical cancer [3]. This conclusion was based solely on the accuracy of the detection methods and assumptions that were used to attribute causality to HPV genotypes 16 and 18.

Whilst PCR methods are more sensitive and specific than liquid hybridization techniques and enable the identification of different genotypes, the specificity of this technique depends upon the type of primer used: type-specific or broad-spectrum [6]. The Bosch et al. 1995 study used the broad-spectrum MY11/09 method to genotype HPV-DNA [7]. The nascent technology used in this study was only available from the mid-nineties so the evidence for the causality of different HPV genotypes was based on a small number of studies between 1995 and 2002. Prior to 2002 a multi-factorial etiology was believed likely with HPV being a necessary factor but not a sufficient cause[2].

By 2002 scientists were proposing that human papillomavirus (HPV) Type 16 and 18 was the ‘first ever identified necessary cause of human cancer’ [3]. This suggests that cervical cancer does not and will not develop in the absence of HPV DNA [3]. The claim hasn’t been sustained because some investigators observe that HPV infection cannot be found in every patient with cervical cancer [2]. Scientists have found that persistent infection with one of 15 genotypes of HPV can lead to cervical cancer and it is stated that HPV genotypes 16 and 18 are the cause of the majority of cervical cancer worldwide [3,8]. The International Agency for Research on Cancer (IARC) working group also acknowledged in 2005 that there are cofactors that are associated with HPV infection and cancer development [9]. In other words, an HPV infection does not progress to cancer without the co-factors being present.

Several risk factors have been identified including infection with other sexually transmitted infections (STI’s), high parity, smoking and hormonal contraceptives [9]. The strength of these risks (co-factors) is variable and even though it was known in 2002 that co-factors were required for pathogenesis it was still believed that a vaccine targeting HPV 16 and 18 would prove effective[9].

Clinical trials to test the hypothesis that the quadrivalent HPV vaccine would be effective against cervical cancer, and not just the prevention of HPV 16/18 infection, were started in phase 3 trials in 2003 [10,11]. These trials investigated pre-cancerous lesions in 12,167 women (15–26 years old) and were completed in 2007 [10]. Yet the quadrivalent HPV vaccine was approved for the European and US market in 2006 [12,13]. The HPV vaccine, Gardasil® was developed and marketed to women as an effective prevention for cervical cancer after only 4 years of testing for efficacy against pre-cancerous lesions [11,14].

This paper examines the epidemiology of HPV infection and its progression to cervical cancer in different countries. It analyses the assumptions that have been made to claim that a vaccine against cervical cancer is cost-effective (CE) in countries with already established Pap screening programs. The cost-effectiveness of HPV vaccines has been determined using mathematical models that are limited by the assumptions they are based on [15]. An independent assessment of these assumptions is essential to population health and the effective distribution of health resources to the community. This paper provides an independent assessment of these assumptions and re-evaluates the cost effectiveness of broad vaccination programs that have been implemented in many countries.

The electronic version of this article is the complete one and can be found online here.

© 2013 Wilyman; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related

Filed Under: Cervarix Vaccine, Gardasil/Silgard Vaccine, HPV, HPV Science, Immunization Practices, Vaccine Science Tagged With: cost effectiveness, developed countries, HPV VACCINES

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Gardasil Vaccine: One more girl dead

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Is 'protecting' against 4 types of HPV enough to warrant the risks?

HPV vaccine documentary Japan. Gardasil and Cervarix

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2025 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in